What Is Retatrutide?
Retatrutide is a synthetic peptide that acts as a triple agonist at three metabolic receptors: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). This triple-agonist mechanism distinguishes it from dual agonists like tirzepatide (GLP-1/GIP) and single agonists like semaglutide (GLP-1 only).
Mechanism of Action
By simultaneously activating GLP-1R, GIPR, and GCGR, retatrutide engages multiple metabolic pathways. GLP-1R activation supports insulin secretion and reduces appetite. GIPR activation enhances insulin secretion in a glucose-dependent manner and may contribute to lipid metabolism. GCGR activation stimulates hepatic glucose production and increases energy expenditure through thermogenesis and fatty acid oxidation. The combination of all three pathways is hypothesised to produce additive or synergistic effects on energy balance and glycaemic control.
Research Context
Retatrutide has generated substantial scientific interest following Phase 1 and Phase 2 clinical trial data published in peer-reviewed journals. Preclinical and early clinical data indicate significant effects on body weight reduction and metabolic parameters in research subjects. The compound is actively researched as a model for next-generation incretin-based metabolic therapies and is studied in the context of obesity, type 2 diabetes, non-alcoholic fatty liver disease (NAFLD), and cardiovascular risk reduction.
Research Considerations
Retatrutide is a complex molecule requiring careful handling. It is supplied in lyophilised form and requires reconstitution with bacteriostatic water before use in research protocols. Storage at -20°C is recommended for long-term stability. Researchers should be aware of the multi-receptor pharmacology when designing experiments, particularly regarding the glucagon receptor component which has counter-regulatory effects on some GLP-1-mediated processes.
Where to Source Retatrutide in Europe
Peptifly supplies Retatrutide in 10mg lyophilised vials, independently tested for 99%+ purity by a third-party laboratory. We dispatch from EU-based fulfilment centres with temperature-controlled packaging. Browse our catalogue at peptifly.com/shop.
Frequently Asked Questions
What makes retatrutide different from semaglutide or tirzepatide?
Retatrutide is a triple agonist (GLP-1, GIP, glucagon receptors), whereas semaglutide targets only GLP-1R and tirzepatide targets GLP-1R and GIPR. The addition of glucagon receptor agonism may produce greater energy expenditure effects.
Is retatrutide approved for clinical use?
As of early 2026, retatrutide is in clinical development and has not received regulatory approval. It is available strictly for research purposes from Peptifly.
Where can I buy retatrutide in Europe?
Peptifly supplies retatrutide 10mg vials with EU dispatch and independent purity verification. Order at peptifly.com/shop.
Disclaimer: All peptides sold by Peptifly are strictly for research and laboratory use only. This article is for informational purposes only.